Skip to main content
. 2021 Feb 7;13(4):669. doi: 10.3390/cancers13040669

Figure 6.

Figure 6

Exemplification of the synthetic lethality concept by PARP1 inhibition in BRCA1-deficient cancer cells. When the pharmacological inhibition of PARP1 combines with lack of wild type (WT) compensation mechanism (BRCA1) in cancerous cells, these cells become substantially more vulnerable to the treatment.